Ovarian carcinoma: adjuvant treatment with P-32

Journal Article · Thu Oct 01 04:00:00 EDT 1987 · Radiology; (United States)

DOI:https://doi.org/10.1148/radiology.165.1.3628782· OSTI ID:5901096

Reddy, S; Sutton, G P; Stehman, F B; Hornback, N B; Ehrlich, C E

Twenty-eight patients with ovarian carcinoma received 555 MBq of labeled chromic phosphate (P-32) intraperitoneally. Indications for treatment included a high-grade tumor, extracapsular involvement, positive cytologic findings, or residual tumor. Fifteen patients (group 1) had stage I, II, or III completely resected tumor; 13 patients (group 2) had microscopic or less than 3-mm lesions at second-look laparotomy following combination chemotherapy. A major complication occurred in one patient; two patients had minor complications. Overall, 24 of 28 patients (85.7%) were alive at 11-77 months; 23 (82.1%) had no evidence of tumor. Fifteen of 15 (100%) group 1 patients and eight of 13 (61.5%) group 2 patients did not have tumor relapse after 30 months and 28 1/2 months, respectively. P-32 was found to be an effective adjuvant treatment in a select group of patients with ovarian carcinoma who were at high risk for intraabdominal recurrence.

• Research Organization: Indiana Univ. School of Medicine, Indianapolis
• OSTI ID: 5901096
• Journal Information: Radiology; (United States), Journal Name: Radiology; (United States) Vol. 165:1; ISSN RADLA
• Country of Publication: United States
• Language: English

Related Subjects

550600 -- Medicine
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CARCINOMAS
CHROMIUM
COMBINED THERAPY
DAYS LIVING RADIOISOTOPES
DISEASES
ELEMENTS
FEMALE GENITALS
GONADS
INJECTION
INTAKE
INTRAPERITONEAL INJECTION
ISOTOPES
LIGHT NUCLEI
METALS
NEOPLASMS
NUCLEI
ODD-ODD NUCLEI
ORGANS
OVARIES
OXYGEN COMPOUNDS
PATIENTS
PHOSPHATES
PHOSPHORUS 32
PHOSPHORUS COMPOUNDS
PHOSPHORUS ISOTOPES
RADIOISOTOPES
THERAPY
TRANSITION ELEMENTS